Yoo Byeong-ho, a member of the Board of Audit and Inspection, has lost his lawsuit challenging a decision recognizing the job relevance of stocks held by his spouse.
According to legal sources on the 20th, Yoo submitted a withdrawal of appeal to the Seoul High Court's Administrative Division 10-2 on the 2nd. As a result, the first-instance ruling of loss for the plaintiff has been finalized.
Under the Public Official Ethics Act, public officials subject to property disclosure must sell or place in a blind trust any stocks held by themselves or their spouses if the total value exceeds 30 million won (KRW). Stocks deemed not relevant to their duties by the review committee are exempt from this rule.
Yoo's spouse acquired 3,207 shares of the pharmaceutical company CTX in April 2024, valued at approximately 16 million won (KRW). Including this stock, the total value of the non-listed stocks related to his duties held by his spouse exceeded 30 million won (KRW).
The Stock Blind Trust Review Committee determined in November 2024 that the stocks were relevant to Yoo's duties, citing that CTX was subject to an audit by the Board of Audit and Inspection. Yoo sought to annul this decision and applied for a stay of execution. The Seoul Administrative Court dismissed the stay application in March of last year.
The court stated that while there is a possibility of economic loss for Yoo, the need to secure public trust in the fair execution of duties by public officials is greater. The Seoul Administrative Court also ruled against the plaintiff in the main lawsuit on October 17 of last year.
In December 2022, while serving as the Secretary General of the Board of Audit and Inspection, Yoo filed a lawsuit against a decision recognizing the job relevance of stocks worth approximately 820 million won (KRW) held by his spouse in the unlisted bio company GCG Genome. The Seoul Administrative Court ruled against the plaintiff on September 12, 2023.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.